Literature DB >> 17442776

Modulation of immune responses by mesenchymal stem cells.

Willem E Fibbe1, Alma J Nauta, Helene Roelofs.   

Abstract

Mesenchymal stem cells (MSCs) are multipotent progenitor cells and interest in MSC therapy has been raised by the observation that MSCs are able to modulate immune responses in vitro and in vivo. Here, we show that MSCs are not intrinsically immune privileged and are capable of inducing memory T cell responses following injection in vivo in immunocompetent hosts. After cotransplantation in recipients that have received sublethal irradiation, allogeneic MSCs can still induce an alloresponse that may result in graft rejection, suggesting that the immunogenicity of allogeneic MSCs are not fully prevented by a nonmyeloablative conditioning regimen. It is still unclear whether the immunogenicity of allogeneic MSCs is also preserved following a fully myeloablative conditioning regimen.

Entities:  

Mesh:

Year:  2007        PMID: 17442776     DOI: 10.1196/annals.1392.025

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  49 in total

1.  Mesenchymal stem cell stimulation of tissue growth depends on differentiation state.

Authors:  Ashley R Rothenberg; Lee Ouyang; Jennifer H Elisseeff
Journal:  Stem Cells Dev       Date:  2010-11-03       Impact factor: 3.272

2.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

Review 3.  Biomaterial technology for tissue engineering applications.

Authors:  Yasuhiko Tabata
Journal:  J R Soc Interface       Date:  2009-03-04       Impact factor: 4.118

Review 4.  Death and inflammation following somatic cell transplantation.

Authors:  Ian B Copland; Jacques Galipeau
Journal:  Semin Immunopathol       Date:  2011-05-01       Impact factor: 9.623

5.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Authors:  Selim Kuçi; Zyrafete Kuçi; Hermann Kreyenberg; Erika Deak; Kathrin Pütsch; Sabine Huenecke; Chandrasekhar Amara; Stefanie Koller; Eva Rettinger; Manuel Grez; Ulrike Koehl; Hatixhe Latifi-Pupovci; Reinhard Henschler; Torsten Tonn; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

6.  A nondenatured, noncrosslinked collagen matrix to deliver stem cells to the heart.

Authors:  Nicholas A Kouris; Jayne M Squirrell; Jangwook P Jung; Carolyn A Pehlke; Timothy Hacker; Kevin W Eliceiri; Brenda M Ogle
Journal:  Regen Med       Date:  2011-09       Impact factor: 3.806

7.  Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.

Authors:  Marilena Ciciarello; Roberta Zini; Lara Rossi; Valentina Salvestrini; Davide Ferrari; Rossella Manfredini; Roberto M Lemoli
Journal:  Stem Cells Dev       Date:  2012-12-21       Impact factor: 3.272

8.  Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Authors:  Yael Barhum; Sharon Gai-Castro; Merav Bahat-Stromza; Ran Barzilay; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-11-10       Impact factor: 3.444

9.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

10.  Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity.

Authors:  Anahid Jewett; Aida Arasteh; Han-Ching Tseng; Armin Behel; Hobie Arasteh; Wendy Yang; Nicholas A Cacalano; Avina Paranjpe
Journal:  PLoS One       Date:  2010-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.